These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37296917)

  • 1. Pancreatic Cancer:
    Keane F; O'Connor CA; Park W; Seufferlein T; O'Reilly EM
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
    JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
    J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
    Golan T; Hammel P
    J Natl Compr Canc Netw; 2021 Apr; 19(4):469-473. PubMed ID: 33845459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    Perkhofer L; Golan T; Cuyle PJ; Matysiak-Budnik T; Van Laethem JL; Macarulla T; Cauchin E; Kleger A; Beutel AK; Gout J; Stenzinger A; Van Cutsem E; Bellmunt J; Hammel P; O'Reilly EM; Seufferlein T
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
    Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine for
    Principe DR
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
    Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications.
    Gupta M; Iyer R; Fountzilas C
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31835379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
    Stossel C; Raitses-Gurevich M; Atias D; Beller T; Glick Gorman Y; Halperin S; Peer E; Denroche RE; Zhang A; Notta F; Wilson JM; O'Kane GM; Haimov Talmoud E; Amison N; Schvimer M; Salpeter SJ; Bar V; Zundelevich A; Tirosh I; Tal R; Dinstag G; Kinar Y; Eliezer Y; Ben-David U; Gavert NS; Straussman R; Gallinger SJ; Berger R; Golan T
    Cancer Discov; 2023 Aug; 13(8):1826-1843. PubMed ID: 37449843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.
    Wong W; Raufi AG; Safyan RA; Bates SE; Manji GA
    Cancer Manag Res; 2020; 12():2731-2742. PubMed ID: 32368150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
    Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    Perkhofer L; Gout J; Roger E; Kude de Almeida F; Baptista Simões C; Wiesmüller L; Seufferlein T; Kleger A
    Gut; 2021 Mar; 70(3):606-617. PubMed ID: 32855305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    Casolino R; Corbo V; Beer P; Hwang CI; Paiella S; Silvestri V; Ottini L; Biankin AV
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.